Alumis Management
Management criteria checks 2/4
Alumis' CEO is Matt Babler, appointed in Sep 2021, has a tenure of 4.33 years. total yearly compensation is $10.66M, comprised of 5.7% salary and 94.3% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth $980.18K. The average tenure of the management team and the board of directors is 3.8 years and 3.7 years respectively.
Key information
Matt Babler
Chief executive officer
US$10.7m
Total compensation
| CEO salary percentage | 5.68% |
| CEO tenure | 4.3yrs |
| CEO ownership | 0.1% |
| Management average tenure | 3.8yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
Alumis Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Aug 16
News Flash: Analysts Just Made A Substantial Upgrade To Their Alumis Inc. (NASDAQ:ALMS) Forecasts
May 29Alumis: A Best-In-Class TYK2 Inhibitor
Nov 28Alumis: Could This Broken Immunology IPO Become The Next Amgen?
Oct 04Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases
Sep 16CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$245m |
| Jun 30 2025 | n/a | n/a | -US$228m |
| Mar 31 2025 | n/a | n/a | -US$343m |
| Dec 31 2024 | US$11m | US$606k | -US$294m |
| Sep 30 2024 | n/a | n/a | -US$239m |
| Jun 30 2024 | n/a | n/a | -US$189m |
| Mar 31 2024 | n/a | n/a | -US$169m |
| Dec 31 2023 | US$5m | US$516k | -US$155m |
Compensation vs Market: Matt's total compensation ($USD10.66M) is above average for companies of similar size in the US market ($USD3.47M).
Compensation vs Earnings: Matt's compensation has increased whilst the company is unprofitable.
CEO
Matt Babler (60 yo)
Mr. Martin Babler, also known as Matt, Ph D., serves as an Independent Director at 89bio, Inc. since April 13, 2024. He is Independent Member of Sardona Therapeutics, Inc. from May 2025.Mr. Babler was Cha...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.3yrs | US$10.66m | 0.10% $ 980.2k | |
| Chief Scientific Officer | 4.3yrs | US$3.24m | 0.21% $ 2.0m | |
| Chief Business & Strategy Officer | 1.2yrs | US$3.22m | 0.18% $ 1.7m | |
| Chief Financial Officer | 3.7yrs | no data | no data | |
| Chief Legal Officer & Corporate Secretary | less than a year | no data | 0.0011% $ 9.9k | |
| Senior VP & Head of Immunology and Translational Science | 4.3yrs | no data | no data | |
| Senior VP of Pharmacology & Project Team Leader | 4.3yrs | no data | no data | |
| Chief Medical Officer & Head of Research and Development | 3.4yrs | no data | 0.0029% $ 26.8k | |
| Chief Development Officer | 4.7yrs | no data | 0.059% $ 555.5k | |
| Senior VP & Head of Technical Operations | 4yrs | no data | no data | |
| Senior VP & Head of Quality and Regulatory | 3.3yrs | no data | no data | |
| Chief Commercial Officer | 1yr | no data | no data |
Experienced Management: ALMS's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.3yrs | US$10.66m | 0.10% $ 980.2k | |
| Independent Director | 4.7yrs | no data | no data | |
| Independent Director | 1.8yrs | US$25.55k | no data | |
| Lead Independent Director | 3.4yrs | US$407.07k | 0% $ 0 | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Independent Director | 1.6yrs | US$532.83k | 0.0068% $ 63.3k | |
| Independent Director | 4yrs | no data | 0.018% $ 164.8k | |
| Independent Director | 4.6yrs | US$432.35k | 0.023% $ 210.7k |
Experienced Board: ALMS's board of directors are considered experienced (3.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/04 02:30 |
| End of Day Share Price | 2026/01/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alumis Inc. is covered by 8 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Eric Schmidt | Cantor Fitzgerald & Co. |
| Yatin Suneja | Guggenheim Securities, LLC |